VEGFA and neoplasm: Apatinib is a novel small-molecule receptor tyrosine kinase inhibitor that inhibits the VEGFR-2 tyrosine kinase’s activity specifically, blocks the VEGF binding to its receptor signalling, and thus potently inhibits tumor angiogenesis.